Verastem, Inc. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Daniel Paterson retiring as CEO after 15 years; Michael P. Bailey (30+ years biopharma, 25+ oncology) appointed President and CEO effective January 1, 2027, remaining on Board as advisor. Simultaneously, VS-7375 KRAS G12D inhibitor demonstrates robust Phase 1/2 data: 50% confirmed ORR in 2L mPDAC (n=8), 41% in 2L+ (n=22), 43% confirmed ORR in 2L+ NSCLC (n=23), 33% ORR in 3L+ CRC (n=6); favorable safety with 2% discontinuation rate at 900 mg QD; FDA alignment reached on Phase 3 1L mPDAC trial design, planned opening by end-2026.
Why this rating
Planned CEO succession with experienced oncology executive is moderately positive governance signal; VS-7375 data (higher response rates than historical KRAS inhibitor comparators) materially advances pipeline—largest commercial asset by far for $254M market-cap company—positioning potential multi-indication franchise. Dual catalysts support trajectory but execution risks remain (pivotal trial outcomes, commercialization, AVMAPKI adoption).
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.